Explore
Validate
LearnMA5-12745
antibody from Invitrogen Antibodies
Targeting: DNAJA1
dj-2, hdj-2, HSJ2, HSPF4, NEDD7
Western blot
Immunocytochemistry Immunoprecipitation
Immunohistochemistry Flow cytometry Other assayAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12745 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-HDJ2 Monoclonal Antibody (KA2A5.6), Biotin
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- MA5-12748 targets HDJ-2/DNAJ in FACS, IF, IHC (P), IP, and WB applications and shows reactivity with Bacteria, Hamster, Human, mouse, Non-human primate, Porcine, Rabbit, and Rat samples. The MA5-12748 immunogen is n-terminal purified recombinant fragment (aa 1-179) of HDJ-2 fusion protein.
- Reactivity
- Human, Mouse, Rat, Bacteria, Hamster, Porcine, Rabbit
- Host
- Mouse
- Conjugate
- Biotin
- Isotype
- IgG
- Antibody clone number
- KA2A5.6
- Vial size
- 500 µL
- Concentration
- 0.2 mg/ml
- Storage
- 4° C
Submitted references Ultrasound safety with midfrequency transcranial sonothrombolysis: preliminary study on normal macaca monkey brain.
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Heat shock protein 40/DjB1 is required for thermotolerance in early phase.
Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions.
Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus.
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Shimizu J, Fukuda T, Abe T, Ogihara M, Kubota J, Sasaki A, Azuma T, Sasaki K, Shimizu K, Oishi T, Umemura S, Furuhata H
Ultrasound in medicine & biology 2012 Jun;38(6):1040-50
Ultrasound in medicine & biology 2012 Jun;38(6):1040-50
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, Andres DA, Spielmann HP, Hrycyna CA, Fong LG, Young SG
The Journal of biological chemistry 2008 Apr 11;283(15):9797-804
The Journal of biological chemistry 2008 Apr 11;283(15):9797-804
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW
Blood 2007 Oct 1;110(7):2674-84
Blood 2007 Oct 1;110(7):2674-84
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY
Cancer research 2007 May 15;67(10):4973-80
Cancer research 2007 May 15;67(10):4973-80
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG
Proceedings of the National Academy of Sciences of the United States of America 2007 Aug 14;104(33):13432-7
Proceedings of the National Academy of Sciences of the United States of America 2007 Aug 14;104(33):13432-7
Heat shock protein 40/DjB1 is required for thermotolerance in early phase.
Uchiyama Y, Takeda N, Mori M, Terada K
Journal of biochemistry 2006 Dec;140(6):805-12
Journal of biochemistry 2006 Dec;140(6):805-12
Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions.
Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, Oyama F, Nukina N
Journal of neurochemistry 2004 Oct;91(1):57-68
Journal of neurochemistry 2004 Oct;91(1):57-68
Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus.
Berciano MT, Villagra NT, Ojeda JL, Navascues J, Gomes A, Lafarga M, Carmo-Fonseca M
Human molecular genetics 2004 Apr 15;13(8):829-38
Human molecular genetics 2004 Apr 15;13(8):829-38
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4761-71
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4761-71
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ
Blood 2001 Mar 1;97(5):1404-12
Blood 2001 Mar 1;97(5):1404-12
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):3894-903
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):3894-903
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human tonsil stained with HDJ-2 antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic staining of cells.
- Conjugate
- Biotin
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HDJ-2/DNAJ using HDJ-2/DNAJ Monoclonal Antibody (Product # MA5-12745) on Native Human Raji Cells.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HDJ-2/DNAJ using HDJ-2/DNAJ Monoclonal Antibody (Product # MA5-12745) on denatured Human Raji Cells.
- Conjugate
- Biotin
